About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Speaker: Prof. Emmanuel Flamand-Roze is neurologist at Pitié-Salpêtrière Hospitala and Professor of Neurology at Sorbonne University in Paris.
Abstract: Dystonia continues to pose a significant challenge to clinicians, with diagnosis mainly based on the history and the description of motor signs. Non-motor manifestations are also part of the clinical spectrum. In parallel with the broad heterogeneity of clinical manifestations among different types of dystonia, the biological mechanisms also show extensive heterogeneity. In this lecture, we will describe recent updates to its definition and classification and how they may assist clinicians in improving recognition and timely diagnosis. We will also discuss progress in the understanding of its pathogenesis and how it may provide therapeutic perspectives: targeting shared mechanisms needs to be considered alongside more individualized approaches.
Host. Dr. Belén Pérez Dueñas. Head of group Therapeutics and Innovations in Neuropediatrics and other paediatric rare diseases. Vall d'Hebron Research Institute (VHIR).